Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.01 (-0.93%)
Close on Nov 11, 2026Market cap $149.51MP/E –Yield –
Compass Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Compass Therapeutics's total assets was $174.50M at Sep 30, 2026. For fiscal 2025 it was $219.59M, up 56.4% from the year before. The highest annual figure on record is $219.59M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.59M | +56.4% |
| FY2024 | Dec 31, 2024 | $140.40M | -10.5% |
| FY2023 | Dec 31, 2023 | $156.88M | -21.4% |
| FY2022 | Dec 31, 2022 | $199.65M | +29.8% |
| FY2021 | Dec 31, 2021 | $153.76M | +196.2% |
| FY2020 | Dec 31, 2020 | $51.91M | +70.9% |
| FY2019 | Dec 31, 2019 | $30.38M | +649205.4% |
| FY2018 | Dec 31, 2018 | $4.68K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $174.50M | -24.5% |
| Q2 FY2026 | Jun 30, 2026 | $190.17M | +63.0% |
| Q1 FY2026 | Mar 31, 2026 | $205.17M | +56.1% |
| Q4 FY2025 | Dec 31, 2025 | $219.59M | +56.4% |
| Q3 FY2025 | Sep 30, 2025 | $231.26M | +55.1% |
| Q2 FY2025 | Jun 30, 2025 | $116.70M | -25.0% |
| Q1 FY2025 | Mar 31, 2025 | $131.45M | -18.4% |
| Q4 FY2024 | Dec 31, 2024 | $140.40M | -10.5% |
| Q3 FY2024 | Sep 30, 2024 | $149.15M | -12.3% |
| Q2 FY2024 | Jun 30, 2024 | $155.61M | -13.2% |
| Q1 FY2024 | Mar 31, 2024 | $161.14M | -14.3% |
| Q4 FY2023 | Dec 31, 2023 | $156.88M | -21.4% |
| Q3 FY2023 | Sep 30, 2023 | $170.04M | +33.0% |
| Q2 FY2023 | Jun 30, 2023 | $179.18M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $187.98M | +28.3% |
| Q4 FY2022 | Dec 31, 2022 | $199.65M | +29.8% |
| Q3 FY2022 | Sep 30, 2022 | $127.84M | +266.3% |
| Q2 FY2022 | Jun 30, 2022 | $140.26M | +243.2% |
| Q1 FY2022 | Mar 31, 2022 | $146.56M | +204.1% |
| Q4 FY2021 | Dec 31, 2021 | $153.76M | +196.2% |
| Q3 FY2021 | Sep 30, 2021 | $34.90M | -42.5% |
| Q2 FY2021 | Jun 30, 2021 | $40.87M | -42.0% |
| Q1 FY2021 | Mar 31, 2021 | $48.20M | +1286896.0% |
| Q4 FY2020 | Dec 31, 2020 | $51.91M | +70.9% |
| Q3 FY2020 | Sep 30, 2020 | $60.69M | +6880852.4% |
| Q2 FY2020 | Jun 30, 2020 | $70.45M | +1447680.5% |
| Q1 FY2020 | Mar 31, 2020 | $3.75K | -20.0% |
| Q4 FY2019 | Dec 31, 2019 | $30.38M | +1241968.7% |
| Q2 FY2019 | Sep 30, 2019 | $882 | -87.8% |
| Q1 FY2019 | Jun 30, 2019 | $4.87K | – |
| Q4 FY2018 | Dec 31, 2018 | $4.68K | – |
| Q2 FY2018 | Sep 30, 2018 | $2.45K | – |
| Q1 FY2018 | Jun 30, 2018 | $7.23K | – |
See a number that looks wrong?